Market Research Logo

Cardiovascular Drugs Market Global Report 2017 Including: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)Covering: Bristol-Myers Squibb C

Cardiovascular Drugs Market Global Report 2017 Including: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)Covering: Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, and Novartis AG

Innovation of gene testing technologies for the development of personalized medicine for cardiovascular diseases is one of the major trend in the market. Due to the reduction in the cost of gene testing, patients can screen for their predisposition for specific cardiovascular diseases. Gene testing helps in development of personalized pharmacogenomic agents and improved patient monitoring efforts and detect them before an onset of acute care episodes.

The Cardiovascular Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global cardiovascular drugs sector.

Reasons to Purchase

  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Gain a global perspective on the development of the market.
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the cardiovascular drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiovascular drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
  • The Cardiovascular Drugs market section of the report gives context. It compares the cardiovascular drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Cardiovascular Drugs Indicators Comparison.
  • The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope

Markets Covered: Anti-Hypertensive, Hypolipidemics, Anti Thrombotics, Others (Congestive Heart Failure, Anti- Arrythmic And Anti-Anginal Drugs)

Companies Mentioned: Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, and Novartis AG

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Cardiovascular Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.


1. Cardiovascular Drugs Market Characteristics
2. Cardiovascular Drugs Market Size And Growth
2.1. Historic Market Growth
2.1.1. Drivers Of The Market
2.1.2. Restraints On The Market
2.2. Forecast Market Growth
2.2.1. Drivers Of The Market
2.2.2. Restraints On The Market
3. Pestle Analysis
3.1. Political
3.2. Economic
3.3. Social
3.4. Technological
3.5. Legal
3.6. Environmental
4. Cardiovascular Drugs Market Customer Information
5. Cardiovascular Drugs Market Segmentation
5.1. Global Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
5.2. Global Cardiovascular Drugs Market, 2012 - 2020, Historic And Forecast, By Segment
5.3 Global Cardiovascular Drugs Market Trends And Strategies
6. Cardiovascular Drugs Market Regional And Country Analysis
6.1. Global Cardiovascular Drugs Market, 2016, By Region
6.2. Global Cardiovascular Drugs Market, 2012 - 2020, Historic And Forecast, By Region
6.3. Cardiovascular Drugs Market, 2016, By Country
6.4. Cardiovascular Drugs Market, 2012 - 2020, Historic And Forecast, By Country
6.5. Global Pharmaceutical Market Segments, 2016, By Region
6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region
6.7. Global Pharmaceutical Market Segments, 2016, By Country
6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country
7. Global Cardiovascular Drugs Market Comparison With Macro Economic Factors
7.1. Cardiovascular Drugs Market Size, Percentage Of GDP, Global
7.2. Per Capita Average Cardiovascular Drugs Expenditure, Global
8. Cardiovascular Drugs Market Comparison With Macro Economic Factors Across Countries
8.1. Cardiovascular Drugs Market Size, Percentage Of GDP, By Country
8.2. Per Capita Average Cardiovascular Drugs Expenditure, By Country
9. Cardiovascular Drugs Market Comparison With Industry Metrics
9.1. Global Number Of Pharmacists, 2016, By Country
9.2. Global Cardiovascular Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
9.3. Global Number Of Pharma Enterprises, 2016, By Country
9.4. Global Cardiovascular Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
9.5. Global Average Spending On R&D/Product Development, 2016, By Country
9.6. Global Cardiovascular Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
9.8. Global Cardiovascular Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
9.9. Prevalent Cases Of Hypertension, 2014, By Country
9.10. Prevalent Cases Of Parkinsons Disease, 2014, By Country
9.11. Global Number Of General Practitioners 2016, By Country
9.12. Global Cardiovascular Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country
10. Asia-Pacific Cardiovascular Drugs Market
10.1.1. Asia-Pacific Cardiovascular Drugs Market Overview
10.1.2. Asia-Pacific Cardiovascular Drugs Historic Market, 2012 - 2016
10.1.3. Asia-Pacific Cardiovascular Drugs Forecast Market, 2016 - 2020
10.1.4. Asia-Pacific Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
10.2. Asia-Pacific Cardiovascular Drugs Market: Country Analysis
10.3. China Cardiovascular Drugs Market
10.3.1. China Cardiovascular Drugs Market Overview
10.3.2. China Cardiovascular Drugs Historic Market, 2012 - 2016
10.3.3. China Cardiovascular Drugs Forecast Market, 2016 - 2020
10.3.4. China Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
10.3.5. China Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
10.3.6. China Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
10.4. India Cardiovascular Drugs Market
10.4.1. India Cardiovascular Drugs Market Overview
10.4.2. India Cardiovascular Drugs Historic Market, 2012 - 2016
10.4.3. India Cardiovascular Drugs Forecast Market, 2016 - 2020
10.4.4. India Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
10.4.5. India Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
10.4.6. India Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
10.5. Japan Cardiovascular Drugs Market
10.5.1. Japan Cardiovascular Drugs Market Overview
10.5.2. Japan Cardiovascular Drugs Historic Market, 2012 - 2016
10.5.3. Japan Cardiovascular Drugs Forecast Market, 2016 - 2020
10.5.4. Japan Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
10.5.5. Japan Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
10.5.6. Japan Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
10.6. Australia Cardiovascular Drugs Market
10.6.1. Australia Cardiovascular Drugs Historic Market, 2012 - 2016
10.6.2. Australia Cardiovascular Drugs Forecast Market, 2016 - 2020
10.6.3. Australia Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
10.6.4. Australia Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
10.6.5. Australia Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
11. Western Europe Cardiovascular Drugs Market
11.1.1. Western Europe Cardiovascular Drugs Market Overview
11.1.2. Western Europe Cardiovascular Drugs Historic Market, 2012 - 2016
11.1.3. Western Europe Cardiovascular Drugs Forecast Market, 2016 - 2020
11.1.4. Western Europe Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
11.2. Western Europe Cardiovascular Drugs Market: Country Analysis
11.3. UK Cardiovascular Drugs Market
11.3.1. UK Cardiovascular Drugs Market Overview
11.3.2. UK Cardiovascular Drugs Historic Market, 2012 - 2016
11.3.3. UK Cardiovascular Drugs Forecast Market, 2016 - 2020
11.3.4. UK Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
11.3.5. UK Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
11.3.6. UK Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
11.4. Germany Cardiovascular Drugs Market
11.4.1. Germany Cardiovascular Drugs Historic Market, 2012 - 2016
11.4.2. Germany Cardiovascular Drugs Forecast Market, 2016 - 2020
11.4.3. Germany Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
11.4.4 Germany Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
11.4.5 Germany Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
11.5 France Cardiovascular Drugs Market
11.5.1 France Cardiovascular Drugs Historic Market, 2012 - 2016
11.5.2 France Cardiovascular Drugs Forecast Market, 2016 - 2020
11.5.3 France Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
11.5.4 France Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
11.5.5 France Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
11.6. Italy Cardiovascular Drugs Market
11.6.1. Italy Cardiovascular Drugs Historic Market, 2012 - 2016
11.6.2. Italy Cardiovascular Drugs Forecast Market, 2016 - 2020
11.6.3. Italy Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
11.6.4. Italy Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
11.6.5. Italy Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
11.7. Spain Cardiovascular Drugs Market
11.7.1. Spain Cardiovascular Drugs Historic Market, 2012 - 2016
11.7.2. Spain Cardiovascular Drugs Forecast Market, 2016 - 2020
11.7.3. Spain Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
11.7.4. Spain Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
11.7.5. Spain Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
12. Eastern Europe Cardiovascular Drugs Market
12.1.1. Eastern Europe Cardiovascular Drugs Market Overview
12.1.2. Eastern Europe Cardiovascular Drugs Historic Market, 2012 - 2016
12.1.3. Eastern Europe Cardiovascular Drugs Forecast Market, 2016 - 2020
12.1.4 Eastern Europe Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
12.2. Eastern Europe Cardiovascular Drugs Market: Country Analysis
12.3. Russia Cardiovascular Drugs Market
12.3.1. Russia Cardiovascular Drugs Historic Market, 2012 - 2016
12.3.2. Russia Cardiovascular Drugs Forecast Market, 2016 - 2020
12.3.3. Russia Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
12.3.4. Russia Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
12.3.5. Russia Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
13. North America Cardiovascular Drugs Market
13.1.1. North America Cardiovascular Drugs Market Overview
13.1.2. North America Cardiovascular Drugs Historic Market, 2012 - 2016
13.1.3. North America Cardiovascular Drugs Forecast Market, 2016 - 2020
13.1.4. North America Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
13.2. North America Cardiovascular Drugs Market: Country Analysis
13.3. USA Cardiovascular Drugs Market
13.3.1. USA Cardiovascular Drugs Historic Market, 2012 - 2016
13.3.2. USA Cardiovascular Drugs Forecast Market, 2016 - 2020
13.3.3 USA Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
13.3.4. USA Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
13.3.5. USA Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
14. South America Cardiovascular Drugs Market
14.1.1. South America Cardiovascular Drugs Market Overview
14.1.2. South America Cardiovascular Drugs Historic Market, 2012 - 2016
14.1.3. South America Cardiovascular Drugs Forecast Market, 2016 - 2020
14.1.4. South America Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
14.2. South America Cardiovascular Drugs Market: Country Analysis
14.3. Brazil Cardiovascular Drugs Market
14.3.1. Brazil Cardiovascular Drugs Historic Market, 2012 - 2016
14.3.2. Brazil Cardiovascular Drugs Forecast Market, 2016 - 2020
14.3.3. Brazil Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
14.3.4. Brazil Cardiovascular Drugs Percentage Of GDP, 2012 - 2020
14.3.5. Brazil Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020
15. Middle East Cardiovascular Drugs Market
15.1.1. Middle East Cardiovascular Drugs Market Overview
15.1.2. Middle East Cardiovascular Drugs Historic Market, 2012 - 2016
15.1.3. Middle East Cardiovascular Drugs Forecast Market, 2016 - 2020
15.1.4. Middle East Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
16. Africa Cardiovascular Drugs Market
16.1.1. Africa Cardiovascular Drugs Market Overview
16.1.1. Africa Cardiovascular Drugs Market Overview
16.1.2. Africa Cardiovascular Drugs Historic Market, 2012 - 2016
16.1.3. Africa Cardiovascular Drugs Forecast Market, 2016 - 2020
16.1.4. Africa Cardiovascular Drugs Market, 2016, By Segment
Anti-Hypertensive Drugs
Hypolipidemics
Anti Thrombotics
Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)
17. Cardiovascular Drugs Market Competitive Landscape
17.1. Company Profiles
17.2. Bristol-Myers Squibb Company
17.2.1. Overview
17.2.2. Products And Services
17.2.3. Strategy
17.2.4. Financial Performance
17.3. Abbott Laboratories Inc.
17.3.1. Overview
17.3.2. Products And Services
17.3.3. Strategy
17.3.4. Financial Performance
17.4. Astrazeneca Plc
17.4.1. Overview
17.4.2. Products And Services
17.4.3. Strategy
17.4.4. Financial Performance
17.5. Bayer Ag
17.5.1. Overview
17.5.2. Products And Services
17.5.3. Strategy
17.5.4. Financial Performance
17.6. Novartis Ag
17.6.1. Overview
17.6.2. Products And Services
17.6.3. Strategy
17.6.4. Financial Performance
18. Key Mergers And Acquisitions In The Cardiovascular Drugs Market
19. Market Background: Pharmaceutical Drugs Market
19.1.1. Pharmaceutical Drugs Market Characteristics
19.1.2. Pharmaceutical Drugs Market Historic Growth
19.1.2.1. Drivers Of The Market
19.1.2.2. Restraints Of The Market
19.1.3. Pharmaceutical Drugs Market Forecast Growth
19.1.3.1. Drivers Of The Market
19.1.3.2. Restraints Of The Market
19.1.4. Pharmaceutical Drugs Trends And Strategies
19.2. Pharmaceutical Drugs Market Regional And Country Analysis
19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region
19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region
19.2.3. Pharmaceutical Drugs Market, 2016, By Country
19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country
19.2.5 Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors
19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global
19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country
19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market
20. Pharmaceuticals Industry Financial Margins
21. Appendix
21.1. NAICS Definitions Of Industry Covered In This Report
21.2. Abbreviations
21.3. Currencies
21.4. Research Inquiries
21.5. The Business Research Company
21.6. Copyright And Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report